Objective: To characterize structural integrity of the lumbosacral enlargement and conus medullaris within one month after spinal cord injury (SCI).Methods: Lumbosacral cord MRI data were acquired in patients with sudden onset (<7 days) SCI at the cervical or thoracic level approximately one month after injury and in healthy controls. Tissue integrity and loss were evaluated through diffusion tensor (DTI) and T2*‐weighted imaging (cross‐sectional area [CSA] measurements). Associations with the degree of neurological impairment were assessed using linear mixed‐effects models.Results: Twenty‐one patients with SCI showed lower white matter (WM) fractional anisotropy (FA) (≤−13.3%) and higher WM radial diffusivity (≤14.6%) compared to 27 healthy controls. Differences were most pronounced in the lateral columns of WM. CSA measurements revealed no group differences. For the lateral columns, lower FA values were associated with lower motor scores and lower amplitudes of motor evoked potentials. For the dorsal columns, lower FA values were associated with lower amplitudes of somatosensory evoked potentials from the lower extremities.Interpretation: One month after SCI, first signs of WM degeneration were apparent, without indication of tissue loss. The more pronounced differences observed in the lateral column could be attributed to anterograde degeneration of the motor tracts. The variability among DTI measurements remote from the lesion site can be partially explained by the degree of the SCI‐induced neurological impairment. Together with previous studies, our findings indicate that impaired tissue integrity precedes tissue loss. The presented techniques have potential applications in monitoring the progression of various neurological diseases.
Background/Objectives: We aimed to evaluate temporal changes in patient selection, surgical practice, and postoperative outcomes of radical prostatectomy in Switzerland (2020–2025) using a national registry. Methods: Data from 7687 patients undergoing radical prostatectomy were extracted from a prospective national registry (January 2020–March 2025). Preoperative, operative, and postoperative variables were compared descriptively using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Temporal trends were assessed using locally estimated scatterplot smoothing. Multivariable logistic regression analyses were performed for positive surgical margins and PSA persistence. Results: Baseline patient characteristics remained stable over time. The use of MRI-targeted biopsy increased from 46% to 84% (p < 0.001). The proportion of low-risk diseases being treated decreased from 7.1% to 4.0% (p = 0.040). Minimally invasive surgery increased from 81% to 95% (p < 0.001); pelvic lymph node dissection declined from 83% to 63% (p < 0.001). Operative time (205 vs. 185 min, p = 0.002) and blood loss (300 vs. 200 mL, p < 0.001) decreased over time. Lymph node invasion decreased from 11% to 6.0% (p = 0.001), positive surgical margins from 27% to 22% (p = 0.044), and prostate-specific antigen persistence from 18.5% to 11.3% (p = 0.001). Severe postoperative complications decreased from 2.5% to 0.8% (p = 0.014). After multivariable adjustment, surgery performed in 2024 remained independently associated with lower rates of positive surgical margins (OR 0.73, 95% CI 0.57–0.93) and PSA persistence (OR 0.26, 95% CI 0.19–0.37) compared with 2020. Conclusions: Using the Swiss national registry, we demonstrate that radical prostatectomy has evolved toward more risk-adapted patient selection, near-universal minimally invasive surgery, and more selective pelvic lymph node dissection. Despite a shift away from low-risk disease, perioperative and early oncological outcomes improved, likely reflecting a combination of evolving diagnostic pathways, increasing surgical experience, and broader changes in perioperative management.
Background: Guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment alternative to patients who are surgically inoperable, or decline radical cystectomy. Objective: The aim of this study was to evaluate oncological outcomes in patients receiving epirubicin-based HIVEC as a second-line therapeutic approach. Methods: Retrospective inclusion of patients from our prospectively maintained, multicenter HIVEC database, who underwent HIVEC due to recurrent or persistent high-grade NMIBC following adequate BCG therapy (BCG failure) between November 2016 and December 2024. Survival was evaluated using Kaplan–Meier analysis and log-rank testing. Associations between clinicopathological factors and oncological outcomes were assessed using Cox regression analysis. Results: Sixty-five patients were included. Median follow-up was 38 months (IQR 21–55). Twenty-four patients (36.9%) experienced intravesical recurrence with a median intravesical recurrence-free survival (RFS) of 24 months (IQR 9-45) and 1-/2-year intravesical RFS rates of 77.9% and 64.1%, respectively. Extravesical recurrence was observed in 21 patients (32.3%) with a median extravesical RFS of 22 months (IQR 7-43) and 1-/2-year extravesical RFS rates of 81.3% and 70.9%, respectively. Higher number of recurrences prior to HIVEC were significantly associated with extravesical recurrence in univariate (HR 2.23; 95% CI 1.23-3.87; p=0.019) and multivariate analysis (HR 1.31; 95% CI 1.03-1.67; p=0.027). Conclusions: Although limited by the relatively small sample size, Epirubicin-based HIVEC demonstrated promising oncological outcomes indicating its potential value as bladder-preserving treatment option after BCG failure. Prospective controlled studies are warranted to further assess the role of epirubicin-based HIVEC in this setting.
Objective: To determine the incidence of severe 30-day complications (Clavien–Dindo ≥ III) after ultrasound-guided percutaneous suprapubic catheter placement in patients with neurogenic lower urinary tract dysfunction and to describe overall 30-day safety outcomes. Methods: This retrospective single-centre cohort study included adults with neurogenic lower urinary tract dysfunction who underwent first-time, non-urgent ultrasound-guided percutaneous suprapubic catheter placement between January 2019 and April 2025 and had documented follow-up for at least 30 days. Complications were graded according to the Clavien–Dindo classification; severe complications were defined as grade ≥ III. Potential risk factors were assessed using univariable logistic regression. Results: Of 300 screened patients, 287 were included. Within 30 days, 49/287 patients (17.1%; 95% CI 12.9–21.9) developed at least one complication, and 18/287 (6.3%; 95% CI 3.8–9.7) had a Clavien–Dindo grade ≥ III complication. Grade ≥ IIIb events occurred in 6/287 patients (2.1%; grade IIIb, n = 5; grade IV, n = 1). No confirmed bowel injury was observed. In an exploratory univariable analysis, diabetes mellitus showed a borderline unadjusted association with severe complications (OR 2.86; 95% CI 1.01–7.64; p = 0.049). No multivariable adjustment or multiplicity correction was performed. Conclusions: This study provides confirmatory real-world short-term safety data for selected patients with neurogenic lower urinary tract dysfunction who underwent ultrasound-guided trocar suprapubic catheter placement. No confirmed bowel injury was observed. The diabetes mellitus signal is hypothesis-generating and requires confirmation in larger studies.
Urodynamic investigation (UDI) is the gold standard for evaluating refractory lower urinary tract symptoms but may cause pain, emotional discomfort, and adverse events, particularly urinary tract infections. In this secondary analysis of a randomized controlled trial, adults undergoing UDI for neurogenic lower urinary tract dysfunction rated pain and emotional discomfort on an 11-point numeric rating scale (0–10), with ≥ 4 defining moderate-to-severe burden; a structured telephone interview at 7–14 days assessed post-procedural adverse events. Among 490 patients, most reported low pain and emotional discomfort (median 2, IQR 0–4 and 0–5). Pain did not differ by sex, whereas emotional discomfort was higher in females (median 2.5 vs 1; p = 0.004). Post-procedural symptoms included pain (30%), worsening lower urinary tract symptoms (18%), and macrohematuria (8%); 99% were transient. Urinary tract infection occurred in 6% and was associated with pre-procedural bacteriuria (OR 6.69; 95% CI 2.15–20.81). Assuming risk equalization, the number needed to treat to prevent one infection was 15 (95% CI 9.6–38.6). In conclusion, UDI is generally well tolerated, although approximately one-third of patients experience moderate-to-severe pain or emotional discomfort. Pre-procedural bacteriuria increases infection risk, but the number needed to treat does not support antibiotic prophylaxis.